IP Library Granted Patent US 12,575,833
Granted Patent B2
US 12,575,833 · App. 17/398,969 · Granted Mar 17, 2026

Balloon catheter for transcarotid procedures

Inventors: Natasha Johnston (Sunnyvale, CA); Stewart M. Kume (Sunnyvale, CA); Erica J. Rogers (Sunnyvale, CA)
Assignee: BOSTON SCIENTIFIC SCIMED, INC.
A61B17/1204A61B17/12136A61F2/958A61M2025/0008
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,575,833
App. No.
17/398,969
Granted
Mar 17, 2026
Kind
B2
Abstract

Devices and methods establish and facilitate retrograde or reverse flow blood circulation in the region of the carotid artery bifurcation in order to limit or prevent the release of emboli into the cerebral vasculature. Devices and methods are configured for procedures performed through a transcarotid approach for performing transcarotid procedures, including carotid angioplasty, stent deployment, and post stent deployment procedures.

Claims (48)

1 . A transcarotid access and treatment system, comprising:

an arterial access sheath including a sheath defining an internal lumen, the sheath sized and shaped to be introduced into an opening in a common carotid artery of a patient, the arterial access sheath including a proximal sheath end and a distal sheath end, the distal sheath end being configured for insertion into the common carotid artery and the proximal sheath end comprising a single visual alignment marker positioned to be maintained outside of the common carotid artery for viewing outside the patient without fluoroscopic imaging and positioned to be within a field of view of a user during use, wherein the single visual alignment marker is positioned a first distance from the distal sheath end;

a balloon catheter, comprising

a catheter shaft extending between a proximal end and a distal end of the balloon catheter;

a balloon positioned adjacent the distal end of the balloon catheter and configured to transition between a deflated state and an inflated state, the balloon being sized to travel through the internal lumen of the sheath and into the common carotid artery;

a flexible tip extending a second distance from a distal balloon end of the balloon; and

a single visual indicator positioned along the catheter shaft, the single visual indicator configured for naked-eye visualization without fluoroscopic imaging and positioned a third distance from the distal end of the balloon catheter, the first distance and the third distance being the same distance and within a range of approximately 250 millimeters (mm) and approximately 350 mm, wherein alignment of the single visual indicator with the single visual alignment marker of the arterial access sheath outside the patient indicates alignment of a distal end of the flexible tip with a distal lumen end of the internal lumen of the arterial access sheath such that alignment of the single visual indicator and the single visual alignment marker can be directly viewed by the user to allow alignment of the single visual indicator with the single visual alignment marker to be achieved and viewed by the user without the use of fluoroscopy, and

wherein the third distance allows the single visual indicator to be viewed, by direct visual observation without the use of fluoroscopy, by a user while the distal sheath end of the arterial access sheath is positioned in the common carotid artery and while the distal end of the balloon catheter is aligned with the distal lumen end of the internal lumen of the arterial access sheath.

2 . The transcarotid access and treatment system of claim 1 , wherein the distal lumen end is positioned approximately the first distance away from the single visual alignment marker such that the visual alignment relationship between the single visual indicator and the single visual alignment marker provides direct visual confirmation of catheter positioning without requiring fluoroscopic verification.

3 . The transcarotid access and treatment system of claim 1 , wherein the balloon includes a length of approximately 20 mm to approximately 40 mm.

4 . The transcarotid access and treatment system of claim 3 , wherein the balloon catheter further comprises a distal guidewire port positioned adjacent a proximal end of the balloon.

5 . The transcarotid access and treatment system of claim 4 , wherein the balloon catheter further comprises a guidewire lumen extending between the distal guidewire port and a flexible tip guidewire port at a distal end of the flexible tip.

6 . The transcarotid access and treatment system of claim 5 , wherein the distal guidewire port is positioned approximately 245 mm to approximately 255 mm from the distal end of the flexible tip, the guidewire lumen extending through the balloon, and the distal end of the balloon being coupled to one or more of an outer wall of the guidewire lumen and the flexible tip.

7 . The transcarotid access and treatment system of claim 1 , wherein the balloon in an inflated state includes an outer diameter that is approximately 1 mm to approximately 8 mm.

8 . The transcarotid access and treatment system of claim 1 , wherein the single visual indicator includes one or more of an extruded feature, a depressed feature, a number, a letter, and a band extending circumferentially around the catheter shaft, the single visual indicator being configured for direct visual observation without fluoroscopic imaging and distinguishable by naked-eye visualization during use.

9 . The transcarotid access and treatment system of claim 1 , wherein the balloon catheter further comprises a balloon marker positioned along the catheter shaft and within a length of the balloon wherein the balloon marker is visually distinguishable from the single visual indicator and configured for identification separate from the visual alignment system.

10 . A method of a transcarotid access and treatment system, comprising:

inserting a distal end of a balloon catheter into an internal lumen of an arterial access sheath that is introduced into an opening in a common carotid artery of a patient such that a distal lumen end of the internal lumen of the arterial access sheath is positioned in the common carotid artery, the arterial access sheath comprising a proximal sheath end including a single visual alignment marker positioned to be maintained outside of the common carotid artery for viewing outside the patient without fluoroscopic imaging and positioned to be within a field of view of a user during use, the single visual alignment marker positioned a first distance from the distal sheath end, the balloon catheter including a balloon positioned adjacent the distal end of the balloon catheter and configured to transition between a deflated state and an inflated state, the balloon catheter including a flexible tip extending a second distance from a distal balloon end of the balloon;

aligning, without the use of fluoroscopy, through direct visual observation, a single visual indicator positioned along a catheter shaft of the balloon catheter with the single visual alignment marker of the arterial access sheath outside the patient thereby aligning the distal end of the balloon catheter with the distal lumen end of the internal lumen of the arterial access sheath, the single visual indicator positioned a third distance from the distal end of the balloon catheter, the first distance and the third distance being the same distance and within a range of approximately 250 millimeters (mm) and approximately 350 mm, wherein alignment of the single visual indicator and the single visual alignment marker can be directly viewed by the user to allow alignment of the single visual indicator with the single visual alignment marker to be achieved and viewed by the user without the use of fluoroscopy, wherein the third distance allows the single visual indicator to be viewed, by direct visual observation without the use of fluoroscopy, by a user while the distal sheath end of the arterial access sheath is positioned in the common carotid artery and while the distal end of the balloon catheter is aligned with the distal lumen end of the internal lumen of the arterial access sheath; and

advancing the balloon to a treatment site for performing a part of a carotid angioplasty procedure.

11 . The method of claim 10 , further comprising:

delivering a fluid to the balloon positioned at the treatment site to cause the balloon to form the inflated state and apply a circumferential force against an inner wall of a stent to deploy the stent at the treatment site.

12 . The method of claim 10 , further comprising:

delivering a fluid to the balloon positioned at the treatment site to cause the balloon to form the inflated state and apply a circumferential force against an inner wall of a deployed stent to increase a diameter of the deployed stent.

13 . The method of claim 10 , further comprising:

delivering a fluid to the balloon positioned at the treatment site to cause the balloon to form the inflated state and apply a circumferential force against an inner wall of a carotid artery to increase a diameter of the inner wall, the inner wall including a plaque material.

14 . The method of claim 10 , wherein the distal lumen end is positioned approximately the first distance away from the single visual alignment marker.

15 . The method of claim 10 , wherein the balloon includes a length of approximately 20 mm to approximately 40 mm.

16 . The method of claim 15 , wherein the balloon catheter further comprises a distal guidewire port positioned adjacent a proximal end of the balloon.

17 . The method of claim 16 , wherein the balloon catheter further comprises a guidewire lumen extending between the distal guidewire port and a flexible tip guidewire port at a distal end of the flexible tip.

18 . The method of claim 17 , wherein the distal guidewire port is positioned approximately 245 mm to approximately 255 mm from the distal end of the flexible tip, the guidewire lumen extending through the balloon, and the distal end of the balloon being coupled to one or more of an outer wall of the guidewire lumen and the flexible tip.

19 . The method of claim 10 , wherein the balloon in the inflated state includes an outer diameter that is approximately 1 mm to approximately 8 mm.

20 . The method of claim 10 , wherein the single visual indicator includes one or more of an extruded feature, a depressed feature, a number, a letter, and a band extending circumferentially around the catheter shaft.

21 . A balloon catheter, comprising

a catheter shaft extending between a proximal end and a distal end of the balloon catheter;

a balloon positioned adjacent the distal end of the balloon catheter and configured to transition between a deflated state and an inflated state;

a flexible tip extending from a distal balloon end of the balloon; and

a single visual indicator positioned along the catheter shaft, the single visual indicator configured for naked-eye visualization without fluoroscopic imaging and positioned a first distance from the distal end of the balloon catheter, the first distance being within a range of approximately 250 millimeters (mm) and approximately 350 mm, wherein alignment of the single visual indicator with a single visual alignment marker positioned along a proximal sheath end of an arterial access sheath and a third distance from a distal lumen end of the internal lumen indicates alignment of the distal end of the balloon catheter with a distal lumen end of the internal lumen of the arterial access sheath such that alignment of the single visual indicator and the single visual alignment marker can be directly viewed by the user to allow alignment of the single visual indicator with the single visual alignment marker to be achieved and viewed by the user without the use of fluoroscopy, the single visual alignment marker of the arterial access sheath being positioned the first distance from the distal lumen and configured to be maintained outside of the common carotid artery of a patient for viewing outside the patient without fluoroscopic imaging and positioned to be within a field of view of a user during use, and wherein the third distance allows the single visual indicator to be viewed, by direct visual observation without the use of fluoroscopy, by a user while a distal sheath end of the arterial access sheath is positioned in the common carotid artery and while the distal end of the balloon catheter is aligned with the distal lumen end of the internal lumen of the arterial access sheath.

22 . The balloon catheter of claim 21 , wherein the balloon includes a length of approximately 20 mm to approximately 40 mm.

23 . The balloon catheter of claim 22 , further comprising:

a distal guidewire port positioned adjacent a proximal end of the balloon.

24 . The balloon catheter of claim 23 , further comprising:

a guidewire lumen extending between the distal guidewire port and a flexible tip guidewire port at a distal end of the flexible tip.

25 . The balloon catheter of claim 24 , wherein the distal guidewire port is positioned approximately 245 mm to approximately 255 mm from the distal end of the flexible tip, the guidewire lumen extending through the balloon, and the distal end of the balloon being coupled to one or more of an outer wall of the guidewire lumen and the flexible tip.

26 . The balloon catheter of claim 21 , wherein the balloon in an inflated state includes an outer diameter that is approximately 1 mm to approximately 8 mm.

27 . The balloon catheter of claim 21 , wherein the single visual indicator includes one or more of an extruded feature, a depressed feature, a number, a letter, and a band extending circumferentially around the catheter shaft.

28 . The balloon catheter of claim 21 , further comprising:

a balloon marker positioned along the catheter shaft and within a length of the balloon.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2025
From: SILK ROAD MEDICAL, INC.
To: BOSTON SCIENTIFIC SCIMED, INC.
Reel/Frame 070671/0426 →
RELEASE OF SECURITY INTEREST Recorded Sep 17, 2024
From: OXFORD FINANCE, LLC
To: SILK ROAD MEDICAL, INC.
Reel/Frame 068979/0196 →
SECURITY INTEREST Recorded Jul 11, 2023
From: SILK ROAD MEDICAL, INC.
To: OXFORD FINANCE LLC
Reel/Frame 064252/0197 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 30, 2021
From: JOHNSTON, NATASHA; KUME, STEWART M.; ROGERS, ERICA J.
To: SILK ROAD MEDICAL, INC.
Reel/Frame 058509/0816 →
Continuity (2)
Provisional Application 63064374 · Aug 11, 2020
Related Publication 20220047267A1 · Feb 17, 2022
References Cited (135)
US 5727594A · Choksi · 1998 [cited by applicant]
US 5779731A · Leavitt · 1998 [cited by applicant]
US 5876374A · Alba · 1999 [cited by examiner]
US 6165162A · Safar · 2000 [cited by examiner]
US 6248092B1 · Miraki et al. · 2001 [cited by applicant]
US 6346089B1 · Dibie · 2002 [cited by examiner]
US 6413235B1 · Parodi · 2002 [cited by applicant]
US 6423032B2 · Parodi · 2002 [cited by applicant]
US 6595953B1 · Coppi et al. · 2003 [cited by applicant]
US 6610069B2 · Euteneuer et al. · 2003 [cited by applicant]
US 6723113B1 · Shkolnik · 2004 [cited by examiner]
US 6837881B1 · Barbut · 2005 [cited by applicant]
US 6994687B1 · Shkolnik · 2006 [cited by examiner]
US 7083594B2 · Coppi · 2006 [cited by applicant]
US 7387639B2 · Bourang et al. · 2008 [cited by applicant]
US 7909797B2 · Kennedy, II et al. · 2011 [cited by applicant]
US 8545552B2 · Garrison · 2013 [cited by examiner]
US 10357361B2 · Rafi · 2019 [cited by examiner]
US 10668258B1 · Calhoun · 2020 [cited by examiner]
US 20010044598A1 · Parodi · 2001 [cited by examiner]
US 20020169377A1 · Khairkhahan · 2002 [cited by examiner]
US 20020173835A1 · Bourang · 2002 [cited by examiner]
US 20050154349A1 · Renz et al. · 2005 [cited by applicant]
US 20050221072A1 · Dubrow · 2005 [cited by examiner]
US 20090048655A1 · Jang · 2009 [cited by examiner]
US 20090198172A1 · Garrison et al. · 2009 [cited by applicant]
US 20090254166A1 · Chou et al. · 2009 [cited by applicant]
US 20100046332A1 · Suzuki · 2010 [cited by examiner]
US 20100204684A1 · Garrison et al. · 2010 [cited by applicant]
US 20100228269A1 · Garrison et al. · 2010 [cited by applicant]
US 20110004147A1 · Renati et al. · 2011 [cited by applicant]
US 20110015729A1 · Jimenez · 2011 [cited by examiner]
US 20110118774A1 · Solar · 2011 [cited by examiner]
US 20110307047A1 · Bourang · 2011 [cited by examiner]
US 20130197621A1 · Ryan · 2013 [cited by examiner]
US 20140172003A1 · Goepfrich · 2014 [cited by examiner]
US 20140296769A1 · Hyde et al. · 2014 [cited by applicant]
US 20150148601A1 · Weiner et al. · 2015 [cited by applicant]
US 20150231375A1 · Kubo · 2015 [cited by examiner]
US 20160242764A1 · Garrison et al. · 2016 [cited by applicant]
US 20160296690A1 · Kume · 2016 [cited by examiner]
US 20160317288A1 · Rogers · 2016 [cited by examiner]
US 20170021139A1 · Bajema et al. · 2017 [cited by applicant]
US 20170296798A1 · Kume · 2017 [cited by examiner]
US 20170325977A1 · Sarac · 2017 [cited by examiner]
US 20180353732A1 · Fuller et al. · 2018 [cited by applicant]
US 20190125512A1 · MacDonald · 2019 [cited by examiner]
US 20190366070A1 · Kume et al. · 2019 [cited by applicant]
US 20190388654A1 · Chou et al. · 2019 [cited by applicant]
US 20200009406A1 · Garrison et al. · 2020 [cited by applicant]
US 20200054871A1 · Ryan et al. · 2020 [cited by applicant]
US 20200171277A1 · Garrison et al. · 2020 [cited by applicant]
US 20200282127A1 · Garrison et al. · 2020 [cited by applicant]
US 20200352713A1 · Pintor · 2020 [cited by examiner]
US 20200375729A1 · Garrison et al. · 2020 [cited by applicant]
US 20200390438A1 · Garrison et al. · 2020 [cited by applicant]
US 20200397472A1 · MacDonald et al. · 2020 [cited by applicant]
US 20210145453A1 · Kume · 2021 [cited by applicant]
US 20210205571A1 · Chang · 2021 [cited by applicant]
US 20210212679A1 · Hentges et al. · 2021 [cited by applicant]
US 20210220108A1 · Zhadkevich · 2021 [cited by examiner]
US 20210228847A1 · Kume et al. · 2021 [cited by applicant]
US 20210244522A1 · Rogers et al. · 2021 [cited by applicant]
US 20210251634A1 · Chang · 2021 [cited by applicant]
US 20210290213A1 · Garrison · 2021 [cited by applicant]
US 20210290257A1 · Garrison et al. · 2021 [cited by applicant]
US 20210298929A1 · Wallace et al. · 2021 [cited by applicant]
US 20210299343A1 · Criado et al. · 2021 [cited by applicant]
US 20210299425A1 · Kume et al. · 2021 [cited by applicant]
US 20210307945A1 · Chou et al. · 2021 [cited by applicant]
US 20210322738A1 · Kume et al. · 2021 [cited by applicant]
US 20210401597A1 · Keating · 2021 [cited by examiner]
US 20220000896A1 · Ning · 2022 [cited by examiner]
US 20220111177A1 · Chou · 2022 [cited by examiner]
US 20220296183A1 · Lochan · 2022 [cited by examiner]
JP H10503673A · 1998 [cited by applicant]
JP 2017523020A · 2017 [cited by applicant]
WO 2016018781A1 · 2016 [cited by applicant]
U.S. Appl. No. 16/281,311, filed Feb. 21, 2019, US 2019-0388654. [cited by applicant]
U.S. Appl. No. 16/299,524, filed Mar. 12, 2019, US 2019-0366070. [cited by applicant]
U.S. Appl. No. 16/353,492, filed Mar. 14, 2019, US 2020-0009406. [cited by applicant]
U.S. Appl. No. 16/377,663, filed Apr. 8, 2019, US 2019-0231962. [cited by applicant]
U.S. Appl. No. 16/513,030, filed Jul. 16, 2019, US 2020-0170637. [cited by applicant]
U.S. Appl. No. 16/544,083, filed Aug. 19, 2019, US 2020-0171277. [cited by applicant]
U.S. Appl. No. 16/880,594, filed May 21, 2020, US 2020-0282127. [cited by applicant]
U.S. Appl. No. 16/894,474, filed Jun. 5, 2020, US 2020-0297912. [cited by applicant]
U.S. Appl. No. 16/939,396, filed Jul. 27, 2020, US 2020-0397446. [cited by applicant]
U.S. Appl. No. 17/092,635, filed Nov. 9, 2020, US 2021-0228847. [cited by applicant]
U.S. Appl. No. 17/108,711, filed Dec. 1, 2020, US 2021-0212679. [cited by applicant]
U.S. Appl. No. 17/193,962, filed Mar. 5, 2021, US 2021-0290257. [cited by applicant]
U.S. Appl. No. 17/220,718, filed Apr. 1, 2021, US 2021-0290213. [cited by applicant]
U.S. Appl. No. 17/308,199, filed May 5, 2021, US 2021-0251634. [cited by applicant]
PCT/US2020/058365, Oct. 30, 2020, WO 2021/087363. [cited by applicant]
PCT/US2020/058588, Nov. 2, 2020, WO 2021/087480. [cited by applicant]
PCT/US2020/061073, Nov. 18, 2020, WO 2021/102011. [cited by applicant]
Henry, et al. (1999). “Carotid Stenting With Cerebral Protection: First Clinical Experience Using the PercuSurge GuardWire System.” J. Endovasc. Surg. 6:321-331. [cited by applicant]
Ribo, et al. (2006, originally published online Sep. 28, 2006). “Transcranial Doppler Monitoring of Transcervical Carotid Stenting With Flow Reversal Protection: A Novel Carotid Revascularization Technique.” Stroke, 37;… [cited by applicant]
Stejskal, et al. (2007). “Experience of 500 Cases of Neurophysiological Monitoring in Carotid Endarterectomy.” Acta Neurochir, 149:681-689. [cited by applicant]
U.S. Appl. No. 14/227,585, filed Mar. 27, 2014, US 2014-0296769. [cited by applicant]
U.S. Appl. No. 15/049,637, filed Feb. 22, 2016, US 2016-0242764. [cited by applicant]
U.S. Appl. No. 15/399,638, filed Jan. 5, 2017, US 2017-0209260. [cited by applicant]
U.S. Appl. No. 16/530,783, filed Aug. 2, 2019, US 2020-0054871. [cited by applicant]
U.S. Appl. No. 16/906,457, filed Jun. 19, 2020, US 2020-0397472. [cited by applicant]
U.S. Appl. No. 16/951,767, filed Nov. 18, 2020, US 2021-0145453. [cited by applicant]
U.S. Appl. No. 16/999,634, filed Aug. 21, 2020, US 2020-0375728. [cited by applicant]
U.S. Appl. No. 16/999,640, filed Aug. 21, 2020, US 2020-0375729. [cited by applicant]
U.S. Appl. No. 17/000,004, filed Aug. 21, 2020, US 2020-0390438. [cited by applicant]
U.S. Appl. No. 17/074,299, filed Oct. 19, 2020, US 2021-0205571. [cited by applicant]
U.S. Appl. No. 17/149,450, filed Jan. 14, 2021, US 2021-0298929. [cited by applicant]
U.S. Appl. No. 17/179,746, filed Feb. 19, 2021, US 2021-0244522. [cited by applicant]
U.S. Appl. No. 17/206,665, filed Mar. 19, 2021, US 2021-0307945. [cited by applicant]
U.S. Appl. No. 17/237,911, filed Apr. 22, 2021, US 2021-0236790. [cited by applicant]
U.S. Appl. No. 17/307,359, filed May 4, 2021, US 2021-0322738. [cited by applicant]
U.S. Appl. No. 17/345,502, filed Jun. 11, 2021, US 2021-0299343. [cited by applicant]
U.S. Appl. No. 17/345,544, filed Jun. 11, 2021, US 2021-0299425. [cited by applicant]
U.S. Appl. No. 17/406,822, filed Aug. 19, 2021, US 2022-0040502. [cited by applicant]
U.S. Appl. No. 17/555,127, filed Dec. 17, 2021, US 2022-0193321. [cited by applicant]
U.S. Appl. No. 17/684,745, filed Mar. 2, 2022, US 2023-0045964. [cited by applicant]
U.S. Appl. No. 17/749,423, filed May 20, 2022, US 2023-0001161. [cited by applicant]
U.S. Appl. No. 17/749,454, filed May 20, 2022, US 2023-0097442. [cited by applicant]
U.S. Appl. No. 17/773,200, filed Apr. 29, 2022, US 2022-0401111. [cited by applicant]
U.S. Appl. No. 17/773,206, filed Apr. 29, 2022, US 2022-0378565. [cited by applicant]
U.S. Appl. No. 17/899,279, filed Aug. 30, 2022, US 2023-0067426. [cited by applicant]
U.S. Appl. No. 17/951,727, filed Sep. 23, 2022, US 2023-0101242. [cited by applicant]
U.S. Appl. No. 18/071,323, filed Nov. 29, 2022, US 2023-0165696. [cited by applicant]
U.S. Appl. No. 18/301,838, filed Apr. 17, 2023, US 2024-0091424. [cited by applicant]
U.S. Appl. No. 18/448,483, filed Aug. 11, 2023, US 2024-0149028. [cited by applicant]
PCT/US2023/064772, Mar. 21, 2023, WO 2023/183808. [cited by applicant]
PCT/US2023/016058, Mar. 23, 2023, WO 2023/183476. [cited by applicant]
PCT/US2023/023603, May 25, 2023, WO 2023/230277. [cited by applicant]
PCT/US2023/025266, Jun. 14, 2023, WO 2023/244643. [cited by applicant]
PCT/US2023/027339, Jul. 11, 2023, WO 2024/015336. [cited by applicant]
PCT/US2023/028248, Jul. 21, 2023, WO 2024/020142. [cited by applicant]
PCT/US2023/033165, Sep. 19, 2023, WO 2024/064153. [cited by applicant]
PCT/US2023/033949, Sep. 28, 2023, WO 2024/072944. [cited by applicant]